Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3331860 | Hematology/Oncology Clinics of North America | 2007 | 19 Pages |
Abstract
Multiple myeloma (MM) remains incurable despite high-dose chemotherapy with stem cell support. There is need, therefore, for continuous efforts directed toward the development of novel rational-based therapeutics for MM, which requires a detailed knowledge of the mutations driving this malignancy. In improving the success rate of effective drug development, it is equally imperative that biologic systems be developed to better validate these target genes. Here we review the recent developments in the generation of mouse models of MM and their impact as preclinical models for designing and assessing target-based therapeutic approaches.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Constantine S. Mitsiades, Kenneth C. Anderson, Daniel R. Carrasco,